false
Catalog
The American Psychiatric Association Guideline for ...
Presentation Slides
Presentation Slides
Back to course
Pdf Summary
This document is the American Psychiatric Association (APA) Guideline for the Treatment of Patients with Schizophrenia, which was published on January 14th, 2021. It is part of the Clinical Support System for Serious Mental Illness (CSS-SMI), funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) and implemented by the APA. The guideline was developed by a writing group that included experts in schizophrenia and related fields.<br /><br />The guideline provides recommendations for the assessment and treatment of patients with schizophrenia. It emphasizes the use of evidence-based treatments, including pharmacological and nonpharmacological interventions. The use of antipsychotic medications is recommended, with regular monitoring of effectiveness and side effects. Clozapine is specifically recommended for the treatment of treatment-resistant schizophrenia, as well as for patients at risk of suicide or aggressive behavior.<br /><br />In addition to medication, the guideline recommends the use of psychosocial interventions such as cognitive-behavioral therapy, psychoeducation, supported employment, assertive community treatment, and family interventions. It also emphasizes the importance of addressing the specific needs and preferences of individual patients and involving them in the treatment planning process.<br /><br />The guideline provides specific recommendations for the management of adverse effects of antipsychotic medications, including the use of anticholinergic medications for acute dystonia, treatments for parkinsonism and akathisia, and the use of Vmat2 medications for tardive dyskinesia.<br /><br />Overall, the guideline aims to provide clinicians with evidence-based recommendations for the treatment of patients with schizophrenia, with the goal of improving outcomes and quality of life for these individuals.
Keywords
Schizophrenia
Guideline
Treatment
Antipsychotic Medications
Clozapine
Psychosocial Interventions
Cognitive-Behavioral Therapy
Medication Management
Adverse Effects
Improving Outcomes
Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.
×
Please select your language
1
English